Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZVRA 
Zevra Therapeutics Inc. (ZVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: ZVRA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.54
1 Year Target Price $22.54
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.18% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 490.91M USD | Price to earnings Ratio 18.55 | 1Y Target Price 22.54 |
Price to earnings Ratio 18.55 | 1Y Target Price 22.54 | ||
Volume (30-day avg) 7 | Beta 0.99 | 52 Weeks Range 6.19 - 13.16 | Updated Date 12/4/2025 |
52 Weeks Range 6.19 - 13.16 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.0332 | Actual -0.01 |
Profitability
Profit Margin 41.86% | Operating Margin (TTM) 15.9% |
Management Effectiveness
Return on Assets (TTM) -7.84% | Return on Equity (TTM) 34.81% |
Valuation
Trailing PE 18.55 | Forward PE 14.66 | Enterprise Value 354122505 | Price to Sales(TTM) 5.82 |
Enterprise Value 354122505 | Price to Sales(TTM) 5.82 | ||
Enterprise Value to Revenue 4.2 | Enterprise Value to EBITDA 5.27 | Shares Outstanding 56297535 | Shares Floating 52326307 |
Shares Outstanding 56297535 | Shares Floating 52326307 | ||
Percent Insiders 0.78 | Percent Institutions 71.39 |
Upturn AI SWOT
Zevra Therapeutics Inc.
Company Overview
History and Background
Zevra Therapeutics Inc., formerly known as KemPharm, was founded in 2006. Initially focused on prodrug technologies and ADHD treatments, it has evolved into a specialty pharmaceutical company focused on rare diseases. The company rebranded to Zevra Therapeutics in 2022 to reflect this shift in focus.
Core Business Areas
- Rare Disease Therapeutics: Focuses on developing and commercializing therapies for rare diseases.
Leadership and Structure
Neil F. McFarlane serves as the President and Chief Executive Officer. The company has a standard corporate structure with departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- OLPRUVA (sodium phenylbutyrate) oral suspension: OLPRUVA is indicated for the treatment of urea cycle disorders (UCDs). Zevra gained rights to OLPRUVA through the acquisition of Acer Therapeutics. While precise market share data is difficult to ascertain, OLPRUVA competes with other UCD treatments like Ravicti (Horizon Therapeutics) and Buphenyl (Bausch Health).
- Arimoclomol: Arimoclomol is a product candidate in development for Niemann-Pick disease type C (NPC). It has orphan drug designation. If approved, potential competitors would be other emerging therapies for NPC. No revenue has been generated as of yet.
Market Dynamics
Industry Overview
The rare disease therapeutics market is experiencing significant growth due to increased awareness, orphan drug designations, and advancements in drug development technologies. This market is characterized by high unmet needs and premium pricing.
Positioning
Zevra Therapeutics is positioned as a specialty pharmaceutical company focused on acquiring, developing, and commercializing therapies for rare diseases. Their competitive advantage lies in their focus on niche markets with limited treatment options and their ability to acquire promising assets.
Total Addressable Market (TAM)
The global rare disease therapeutics market is estimated to be worth hundreds of billions of dollars. Zevra is targeting specific rare disease segments, positioning itself to capture a portion of this market through its focused product pipeline.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases
- Acquisition strategy
- Orphan drug designations
- Experienced management team
Weaknesses
- Limited product portfolio
- Dependence on acquisitions for growth
- High research and development costs
- Reliance on regulatory approvals
Opportunities
- Expanding pipeline through acquisitions or partnerships
- Gaining regulatory approvals for Arimoclomol
- Entering new rare disease markets
- Leveraging orphan drug benefits
Threats
- Competition from larger pharmaceutical companies
- Failure to obtain regulatory approvals
- Patent expiration
- Adverse clinical trial results
- Pricing pressures
Competitors and Market Share
Key Competitors
- HZNP
- VRTS
- ALNY
Competitive Landscape
Zevra is a small player compared to Horizon Therapeutics, Vertex and Alnylam in terms of overall revenue, but it focuses on niche markets with less competition. Zevra needs to focus on executing its regulatory strategies and drug development pipeline in order to compete with the larger players.
Major Acquisitions
Acer Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 37
- Strategic Rationale: Acquisition of Acer brought OLPRUVA, a commercially available drug to treat UCD and expanded its rare disease portfolio.
Growth Trajectory and Initiatives
Historical Growth: Zevra's growth is driven primarily through acquisitions of assets. Historic growth has been somewhat erratic due to dependence on acquisition strategies.
Future Projections: Future growth is dependent on pipeline expansion, regulatory approvals, and commercialization success of its products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include the acquisition of Acer Therapeutics and its product OLPRUVA, and development activities related to Arimoclomol.
Summary
Zevra Therapeutics is a small, emerging pharmaceutical company focused on acquiring and commercializing drugs for rare diseases. The company's acquisition of Acer Therapeutics and its product OLPRUVA is a positive step, but its reliance on acquisitions and regulatory successes creates inherent risks. Future growth will depend on the approval and commercial success of Arimoclomol and other pipeline products. Zevra needs to execute its regulatory strategy to ensure its competitiveness and sustained growth in the sector.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Zevra Therapeutics Investor Relations
- Company SEC Filings (10K, 10Q)
- Various Market Research Reports on Rare Disease Therapeutics
- Yahoo Finance
- Google Finance
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Financial values are approximations based on available data at the time of analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zevra Therapeutics Inc.
Exchange NASDAQ | Headquaters Celebration, FL, United States | ||
IPO Launch date 2015-04-16 | President, CEO & Director Mr. Neil F. McFarlane | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://zevra.com |
Full time employees 59 | Website https://zevra.com | ||
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.